Allied Academics is a well-known organization which is build up on the foundation of various respectful educational and scientific collaborations. This organization was always known for its encouraging scientific temperament. It is established in the year 1997 as Andrew John Publishing Group, which is an expert Medical publisher, which operates in collaboration with the scientific association and societies. This scientific publication has been originated on the base of honored academic and research institutions which includes The Association for Public Safety Communications Officials of Canada (APCO),The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Dementia is one of the biggest global public health challenges facing by our generation. Worldwide, at least 44 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 115 million urban agglomerations on the planet. New York is situated on one of the world's biggest characteristic harbors.
In New York 390,000 population are suffering with Alzheimer’s disease or related dementia. Many statics shows that in 2025, the number of population of aged 65 and older will increase by 18% or approximately 460,000. Various reports show that the number of dementia patient will much increase in countries like Western Europe and North America.
It is estimated that 62% of people with dementia are live in developing countries. At present, over 35 million people worldwide currently are suffering from various type of dementia. Many statics predict that the number of people with dementia will be double by 2030 and more than three times in 2050, which is around 115 million.
New York spends $5779 per month on only memory care. A major public health burden facing New York State, Alzheimer’s is projected to impact 700,000 individuals by 2025. In addition, the disease plays a major economic role by increasing medical costs and affecting employers of caregivers. In New York only Alzheimer’s disease costs more than $20 billion per year.
In current scenario, no specific treatments are available to decrease or stop the brain damage caused by various brain disorders such as Alzheimer’s, vascular dementia etc. In the course of medication, it was found that several medications have temporary effect on symptoms of dementia for some people.
Dementia2018 is an international congress which expects more than 50 speakers and more than 100 participants from all across the world. Dementia 2018 will provide you chance to get expose with the latest research and technology developing in the field of Dementia and Alzheimer’s disease. This is perfect stage to grow you research incite and participate in the scientific discussion. Along with this Dementia2018 will help the participant to develop international academic and business network.
The main focus of the Dementia 2018 will be on Alzheimer’s disease, Dementia, Imaging Techniques associated with Biomarkers, Various Animal models, Geriatrics and Cognitive Disorder, Pathophysiology, Care practice and Awareness, Current Trends and Awareness in Dementia and Alzheimer’s Disease.
Why to Attend?
This platform will give you an international stage to conduct demonstrations, workshops, and symposiums to showcase your services and product. Dementia 2018 will avail you chance to distribute information and to meet potential national and international delegates. Participant can approach the invited scientist to explore the new product line possibility and exchange the idea of developing the novel therapeutics or products. World-renowned speakers, the most recent researches, innovations, and the Novel updates in Dementia field are hallmarks of this congress.
Why New York
In United State New York is the most densely populated city. Situated at the southern tip of the state of New York, the city is the focal point of the New York metropolitan territory, a standout amongst the most crowded urban agglomerations on the planet. Situated on one of the world's biggest characteristic harbors.
In New York 390,000 population are suffering with Alzheimer’s disease or related dementia. Many statics shows that in 2025, the number of population of aged 65 and older will increase by 18% or approximately 460,000. New York also has very well renowned research institute which are doing the excellent work in the field of Dementia and Dementia Care. New York is the most populous city in the USA and fast growing pharmaceutical industry.
In New York many institutes and associations are working in the field of Dementia, Alzheimer’s and other related neurological disorders. Moreover, USA government organize many public awareness and patient caregiving programs in association with various Alzheimer’s/Dementia organizations. New York spends $5779 per month on only memory care. A major public health burden facing New York State, Alzheimer’s is projected to impact 700,000 individuals by 2025. In addition, the disease plays a major economic role by increasing medical costs and affecting employers of caregivers. In New York only Alzheimer’s disease costs ore than $20 billion per year.
Through Dementia 2018 we are trying to provide an interactive platform for the participants joining us all across the world so that they can take advantage of the event to progress in the research field of Dementia and Alzheimer’s Diseases.
· Neurology Professor
· Neurology Assistant and Associate Professor
· Post doctorate and Doctorate
· Dementia Researchers
· Medical College and Hospitals
· Business Entrepreneurs
· Training Institutes
· Software developing companies
· Medical Devices Manufacturing Companies
· Data Management Companies
· Pharmaceutical industries and Biotech Company
· Dementia community, society and associations
· Other experts in Dementia and dementia care
Session on Alzheimer
Alzheimer is the most common type of dementia. It accounts 60 – 80% of dementia. It causes memory loss and other type of cognitive abnormalities which seriously effects day to day life. In America Alzheimer is the 6th principal cause of demise. Currently there is no cure available in the market.
Alzheimer has many symptoms which can be diagnosed in the early stage of disease and the situation can prevented to get worsen. In many cases the cause of Alzheimer is genetic, it inherited from genes, whereas in other cases it is the result of impairment in mechanism of various biochemical process in the body, such as dysfunction of acetylcholine, beta-amyloid etc.
Scientific Session on Dementia
Dementia is a term which generally refers to loss of memory and some other mental abilities (reasoning, ability to think etc…) which affects the person’s day to day life. Alzheimer’s disease is the most common type of disease which covers 50-70% cases. The common symptoms of dementia include emotional problems, problem in finding words, lack of motivation etc. The severity of dementia increases with the person’s age. The other common types of diseases which include dementia are vascular dementia, levy body dementia, and front temporal dementia.
Scientific Session on Vascular Dementia
Vascular Dementia is the second most common symptoms of dementia followed by Alzheimer’s. It is caused mainly due to blockage of blood flow to the brain vessels. Most of the people with this type of dementia face lot of problems with memory, reasoning etc. The changes that occur in vascular dementia affected people may occur suddenly or can be mild too. Vascular Dementia is thought to be irreversible and it is caused by a number of small strokes or sometimes a large stroke preceded or followed by other smaller strokes. Sometimes Vascular Dementia is also called as Vascular Cognitive Impairment.
Scientific Session on Dementia with Lewy bodies
Around 1.4 million individual is suffering for Lewy bodies’ dementia. Because it symptoms resembles to some other diseases such as Alzheimer’s and Parkinson’s so presently it is a widely undiagnosed dementia. Lewy body is structurally a protein called alpha-synuclein. Lewy bodies’ dementia is mainly characterized by deposition of lewy body in brain area which regulates behavior, cognition, and movement. This ailment affects the thinking patterns such as ability to understand visual information, memory and executive function. Patients show fluctuation in alertness and attention and various types of problem in movement such as tremors, difficult walking etc.
Scientific Session on Parkinson’s disease
Parkinson’s disease is a progressive degeneration of central nervous system which affects the motor nervous system of the patients. In initial stage the patients will get tremors and with the progression of disease if severely effects the movement of the body. This session will focus on all the aspects of research such as prognosis, diagnosis, treatments for reducing the symptoms and various other effects.
Session on Dementia Management
In present situation there is no perfect cure for dementia. Currently researchers are focusing on slow development of dementia and to make the patient life well. This session will highlights the various techniques which help in managing and treating the patients well.
Scientific Session on Diagnostics and Biomarker
Alzheimer’s disease is the most common type of dementia which estimates about 26 million people worldwide. It is a serious brain disorder which impacts daily work life of the person. Till date there is no accurate test to show whether the person has dementia and other related diseases. Due to the lack of finding out the cause for the disease, even physicians are not able to detect the accurate disease. Symptoms of the Alzheimer’s disease grow slowly and spread widely over time and thus cause the brain impairment. There is no availability of single test for detecting dementia; instead there are several medical evaluations such as mental status testing, neurological testing, blood test and medical imaging.
Session on Neuro – Imaging in Dementia
Neuro-imaging is the important technique to diagnose the various kind of dementia. It also helps in detecting the various stage of the ailment. With various method of neuro-imaging we can efficiently relocate the affected part. Neuro-imaging helps in doing site specific medication in the brain and other part of the body.
Scientific Session on Pathophysiology of Dementia
Dementia is a symptom associated with specific structural brain diseases and system degeneration. Alzheimer’s disease, which is the most common among all the diseases under dementia, causes cortical-subcortical degeneration of cholinergic neurons and large pyramidal cells in the cerebral cortex. The disease gradually spreads all over the cortex region and deteriorates the function of brain cells. Pathologically the abnormalities are more diffuse and spread in to the sensorimotor cortical too.
Scientific Session on Neuropharmacology
Neuropharmacology is the branch of neurology which deals with the study of drug effect on the cellular mechanism of nervous system and its influence on the human behavior. It focus on the study of neurons and their organic compound interactions, with the goal of developing medicine that have useful effects on neurological operations which are closely connected with the interactions of neurotransmitters, neuropeptides, neurohormones etc. Through these interactions researchers are developing medicine to treat various neurologic disorders like Alzheimer’s, psychological disorders, addictions and lots of others.
Scientific Session on Dementia Treatment and Therapy
CST is a compact treatment for the people with mild to moderate dementia. Based on extensive research evidences, management of dementia recommends the use of group cognitive stimulation for people with mild and moderate dementia irrespective of drug treatments. The treatment can be administered by anyone such as care workers, psychologists, occupational therapists, nurses etc. Places like residencies, hospitals and day centers are appropriate for undergoing the therapy.
Session on Recent Advancement
This session will be including the latest advancements in the field of Dementia and Alzheimer’s disease researches. This will highlights the new case studies which gave insight for improving the life of the patients. It also includes the discussion on recent technology such as regenerative medicine and stem cell and its role in improving the condition of the Dementia patients. This session also give awareness about the neurotoxicity and the importance of nutrition.
About 46 million people in the world has been estimated to be suffering with dementia by 2015 and it may be increased to 50 million (approx. data) by 2017.whereas in America, about 5.5 million people of all ages are estimated to be suffering with dementia. Among 5.5 millions, It’s been calculated that the people under 65 are about 2, 00,000 suffering with dementia which is referred by the term “younger onset dementia”. By 2020, the people above 65 with dementia are estimated around 5.8 million. In America, Alzheimer’s is accounted as the 6th leading cause of death. The cost of cumulative care for Alzheimer’s patients is estimated to be $236 billion in 2016 and the global cost is estimated to be $605 billion which is equal to the 1% of the world gross product. US Scientists have found that at the age of 65, 1/6th of women have more tendencies to develop Alzheimer’s disease compared to the man with chance of 1 in 11. Dementia rates were high among the African-American women compared to that of the Asia-American women and same way is calculated in the case of men in USA. However based on the environmental risk factors, one can develop the symptoms regardless gender.
Goal of world congress on Dementia 2018 is to furnish an outstanding program for exchange of ideas and interventions by the researchers and scientists who have been inventing the new pathways and novel inter cultural methods for various treatments associated with dementia. We strive to make Dementia 2018 a success with your support and eminent talks about the dementia and perspective care and research works on dementia. We assure you the world class facilities and hospitality entirely during the conference.
The 35.6 million people with dementia across world in 2010 are expected to be double by 2030 to about 65.7 million, and nearly double by 2050 to 115.4 million. It is estimated that as many as 5.1 million people of US are thriving with Alzheimer’s disease and it can be increased with the raising ages. There are currently 390,000 New York population with Alzheimer’s disease or related dementia and it is approximated to be doubled by 2025 nearly an increase of 18% especially to the people aged 65 and above. In New York alone, Medicaid for Alzheimer’s costs around $4.5 billion each year which is the highest cost recorded compared with other cities in USA. It is estimated that nearly 1/3 of seniors who die each year have Alzheimer’s or a related Dementia and it is also estimated that there are about 1 million Alzheimer’s and dementia unpaid caregivers.
The risk of dementia increases with the age and causes mainly due to the brain cell degeneration. Due to the dysfunction of blood vessels after degeneration, blood vessels are unable to receive the oxygen levels properly and hence due to the lack in the supply of oxygen, the brain cells are not able to work properly and thus the risk of memory occurs. Based on the physiological factors and genetic relocation the type of dementia varies from individual to individual but the most common disease is Alzheimer’s which attacks 3/4th of dementia population. The risk of dementia is reaching heights in the developing countries and USA stands in the one of the top 5 countries in developing dementia and related diseases.
USA Market report
It is predicted that the global dementia and movement disorder treatment market will grow more than 4% by 2021 compared with the present CAGR .In addition to that the research analysts identifies the need for disease modifying drugs(DMDS) as one of the primary growth factors for this market. The treatment for dementia is conducted through therapeutic approaches that provide symptomatic relief as the drugs intended for the treatment only treat the symptoms. The existing drugs in the market are unable to attack the underlying cause of the disease and prolong the treatment cost and time duration. This will in turn increase the demand for DMD since it will safely modify the progression of a disease.